HUTCHMED (ADR) (HCM)
Develops targeted therapies and immunotherapies, commercializing medicines in China and through global partners.
Something off on this page? Send us feedback.
Develops targeted therapies and immunotherapies for cancer and immunological diseases. It markets three internally developed medicines in China and uses partnerships to commercialize fruquintinib outside China.
Develops, manufactures, and markets targeted therapies and immunotherapies for cancer and immunological diseases. Its Oncology/Immunology business spans discovery through commercialization, while Other Ventures retains China prescription-drug and healthcare distribution activities.
In China, the internally developed medicines are Orpathys, Elunate, and Sulanda. Fruquintinib is marketed as Fruzaqla outside China through Takeda, while savolitinib is partnered with AstraZeneca.
The operating model combines in-house discovery and China commercialization with selected partners in markets outside China. Founded by a CK Hutchison subsidiary, it remains closely connected today to CK Hutchison through its largest shareholder.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | Stifel Nicolaus | Target | Target: — | Target: $45 |
| Sep 8, 2026 | HSBC | Upgrade | ||
| Sep 3, 2026 | Daiwa | Upgrade | Rating: —Target: — | Target: $18.50 |
| Jul 23, 2026 | Goldman Sachs | Reiterate | Rating: —Target: — | Target: $14 |
| May 28, 2026 | Morgan Stanley | Target | Target: $17.50 | Target: $13.60 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.38B · Total debt $94.5M · Total assets $1.74B · Shareholders' equity $1.26B
- Revenue
- $139.1M
- Operating income
- $434.5K
- Net income
- $8.0M
No dividends on record.
| Institutions | 2.48% | 4.33M ADS | |
|---|---|---|---|
| 56 holders · as of Jun 30, 2026 | |||
| Insiders | 0.05% | 84.0K ADS | |
| 2 holders · as of Mar 11, 2026 | |||
| Other | 97.47% | 170.06M ADS | |
| remainder | |||
174.47M ADS as of Sep 5, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Schroder Investment Management GroupInstitution | 0.85% | 1.48M ADS | as of Jun 30, 2026 |
Allianz Asset Management GmbHInstitution | 0.39% | 674,511 ADS | as of Jun 30, 2026 |
State Street CorpInstitution | 0.18% | 313,611 ADS | as of Jun 30, 2026 |
Aia Group LtdInstitution | 0.17% | 291,229 ADS | as of Jun 30, 2026 |
M&G PLCInstitution | 0.14% | 242,791 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- BeOne Medicines (ADR)
Global oncology developer with China commercialization reach
- Zai Lab (ADR)
China-U.S. oncology commercial company with regional and global programs
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| HUTCHMED (ADR) | $14.24 | +1.17% | $2.45B | 136.6 | — | 4.5 | +0.2% |
| BeOne Medicines (ADR) | $363.61 | −1.21% | $39.33B | 5.1 | 46.1 | 6.4 | +29.6% |
| Zai Lab (ADR) | $26.57 | +0.61% | $2.98B | — | — | 6.6 | −3.3% |
| Median | 5.1 | 46.1 | 6.5 | +13.1% |